Product Description
GX-G6 is long-acting GLP-1 based on Genexines proprietary hyFc Platform technology for type 2 diabetes (T2D) targeting both weekly and twice-monthly regimen compared to conventional daily therapeutics.
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Genexine
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 2 Diabetes
Phase 1: Healthy Volunteers|General Diabetes
Recent News Events
Date |
Type |
Title |
---|---|---|
07/20/2021 |
News Article |
Type 2 Diabetes Pipeline Holds a Potential Future in Treatment Scenario. |